The VHH1-based second- and third-generation CAR-T cells were developed, and the third-generation CAR-T cells exhibited enhanced cytotoxicity towards NETs and gastrointestinal cancers in a CDH17-dependent manner in various tumor models without causing off-tumor toxicity [104]. This evidence concerns the gene CDH17 and neoplasm.